非诺贝特通过调控PPARα-FABP4通路减轻肩袖肌肉脂肪浸润
本研究在体外缺氧C2C12肌母细胞和肩袖撕裂修复大鼠模型中评估非诺贝特对脂肪浸润的影响。体外非诺贝特剂量依赖性下调FABP4并上调PPARα;体内局部给药6周后脂肪面积显著低于对照,FABP4表达降低、PPARα升高。结论提示非诺贝特可能通过PPARα-FABP4代谢通路减少脂肪浸润。
要点
- 体外缺氧条件下,非诺贝特10和100微米均显著下调FABP4并上调PPARα,呈剂量依赖性。
- 大鼠肩袖撕裂模型中,非诺贝特组脂肪面积6.66%±10.38%,显著低于对照组46.38%±21.79%。
- 非诺贝特组FABP4表达显著降低、PPARα显著升高,作者认为其可能作为药物重定位候选。
核心结论
- 非诺贝特通过调控PPARα-FABP4代谢通路减少肩袖撕裂后的肌肉脂肪浸润。
- 这些发现支持非诺贝特作为药物重定位候选,用于预防肌肉退变和改善肩袖损伤组织质量的潜力。
研究设计与样本
- 受控实验室研究,包括体外C2C12肌母细胞实验和肩袖撕裂修复大鼠模型。
- 体外:缺氧条件下用非诺贝特10和100微米处理C2C12肌母细胞,qRT-PCR检测FABP4及上游调控因子和脂肪细胞分化相关基因。
- 体内:切断右侧冈上肌腱建立肩袖撕裂模型,术后2天内局部给药非诺贝特20 mg/kg共3次,6周后取冈上肌行组织学分析和qRT-PCR。
主要发现
- 体外缺氧条件下,非诺贝特10微米组FABP4表达0.86±0.12(P<.01),100微米组0.32±0.06(P<.01),对照组1.12±0.17,呈剂量依赖性下调。
- 体外PPARα表达:非诺贝特10微米组2.46±0.10(P<.01),100微米组2.75±0.13(P<.01),对照组1±0.10,呈剂量依赖性上调。
- 体内定量脂肪面积:非诺贝特组6.66%±10.38%,对照组46.38%±21.79%(P<.01),组织学定性评估同样显示脂肪浸润明显抑制。
- 体内基因表达:非诺贝特组PPARα为10.65±7.02,对照组1±0.62(P<005,原文如此),FABP4为非诺贝特组2.64±0.91 vs 对照组5.44±2(P<.05)。
临床怎么用
- 作者认为非诺贝特具有已知临床安全性,可能代表一种通过靶向脂肪浸润改善肩袖修复结局的新型药物策略。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fatty infiltration of the rotator cuff muscle is a critical prognostic factor associated with poor tendon healing and high retear rates after rotator cuff tear (RCT). Recent studies have identified fatty acid binding protein 4 (FABP4) as a hypoxia- and inflammation-responsive lipid chaperone that may drive adipogenic degeneration in injured muscle tissue. PURPOSE: To evaluate whether fenofibrate-a peroxisome proliferator-activated receptor alpha (PPARα) agonist approved for the treatment of hyperlipidemia-could prevent fatty infiltration by modulating FABP4 expression in vitro and in a RCT repair rat model. STUDY DESIGN: Controlled laboratory study. METHODS: The expression of FABP4 under hypoxic conditions was evaluated in C2C12 myoblasts treated with fenofibrate (10 and 100 μm) using quantitative real-time polymerase chain reaction (qRT-PCR). To investigate molecular mechanisms, the expression levels of upstream regulators and adipocyte differentiation-related genes were also measured by qRT-PCR after fenofibrate treatment in the same cell line. For the in vivo study, an RCT model was established by transection of the right supraspinatus tendon. Fenofibrate (20 mg/kg) was locally administered 3 times over 2 days after surgery. At 6 weeks, the supraspinatus muscle was harvested. Fatty infiltration was qualitatively and quantitatively assessed using histological analysis, and the expression of relevant metabolic and adipogenic genes was analyzed by qRT-PCR. RESULTS: In vitro, fenofibrate significantly downregulated FABP4 expression in a dose-dependent manner under hypoxic conditions (fenofibrate, 10 µm: 0.86 ± 0.12 [P < .01]; 100 µm: 0.32 ± 0.06 [P < .01]; control: 1.12 ± 0.17). Expression of PPARα (fenofibrate, 10 µm: 2.46 ± 0.10 [P < .01]; 100 µm: 2.75 ± 0.13 [P < .01]; control: 1 ± 0.10), an upstream regulator of FABP4, was significantly upregulated after treatment in a similarly dose-dependent fashion. In vivo, fenofibrate-treated shoulders demonstrated marked suppression of fatty infiltration, as confirmed by both qualitative histological evaluation and quantitative fat area analysis (fenofibrate: 6.66% ± 10.38%; control: 46.38% ± 21.79% [P < .01]). Gene expression profiling revealed that PPARα was significantly upregulated (fenofibrate: 10.65 ± 7.02; control: 1 ± 0.62 [P < 005]), while FABP4 expression was significantly reduced (fenofibrate: 2.64 ± 0.91; control: 5.44 ± 2 [P < .05]) in the fenofibrate group compared with controls. CONCLUSION: Fenofibrate reduces muscle fatty infiltration by modulating the PPARα-FABP4 metabolic pathway in the setting of RCT. These findings support the potential of fenofibrate as a drug repositioning candidate to prevent muscle degeneration and enhance tissue quality in rotator cuff (RC) injuries. CLINICAL RELEVANCE: Fenofibrate, with its established clinical safety profile, may represent a novel pharmacologic strategy to improve outcomes after RC repair by targeting fatty infiltration.
引用
- Park SJ, Lee YS, Yoon JP, et al. Fenofibrate Attenuates Rotator Cuff Muscle Fatty Infiltration via Modulation of the PPARα-FABP4 Pathway. Am J Sports Med. 2025. PMID: 41123109. doi:10.1177/03635465251382858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。